HC Wainwright reaffirmed their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q2 2024 earnings at ($0.98) EPS, Q3 2024 earnings at ($1.02) EPS, FY2024 […]
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Free Report) shares are going to reverse split before the market opens on Monday, January 22nd. The 1-20 reverse split was announced on Monday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 22nd. Processa Pharmaceuticals Stock Down 25.3 % […]